The stereospecific syntheses of new bicarbocyclic nucleosides are described. The regioisomers were differentiated by selective INEPT NMR studies and the stereochemistry of these compounds was confirmed by differential NOE NMR experiments. Antiviral results are mentioned.
Introduction
There is increasing interest in nucleosides where the oxygen of the furan ring is replaced by a methylene group. Due to the absence of the glycosidic bond, these compounds referred to as carbocyclic nucleosides are more stable with respect to degradation by enzymes such as phosphorylases. 1 Isomeric nucleosides where the base is transposed from the 1'-to the 2'-position can also be viewed as carbocyclic nucleosides because the nucleobase is not attached at the glycosidic position. 2, 3 Many carbocyclic nucleosides are known including those where the ribose unit has been replaced by cyclopropane, 4 cyclobutane, 5 cyclopentane, 6 and cyclohexane. 7 Carbocyclic nucleosides have shown potential as antiviral agents against HIV, HSV and other viruses. [8] [9] [10] Modification of the sugar moiety further to include fused ring systems 11 has expanded the area of carbocyclic nucleosides. However, bicyclo[2.2.1]carbocyclic nucleosides have not been synthesized or investigated and this is the subject of this communication. Our targeted nucleosides have the secondary hydroxyl group whereas standard nucleosides have the primary hydroxyl group. It has been well known that some biologically active compounds, such as 5′-noraristeromycin, 12 have a secondary hydroxyl group instead of hydroxymethyl group. We wish 
Scheme 1
Hydroboration of 3 was accomplished by using 4 equivalents of BH 3 -THF in THF, followed by oxidation with 30% H 2 O 2 and 2N NaOH(aq) to afford two regioisomers in 80% yield: norbornan-6(R)-ol (4) as a major product (45%) and norbornan-5(S)-ol (5) as a minor product (35%) (Scheme 1). These regioisomers were separated by reversed-phase HPLC on Amberlite XAD-4 resin as the stationary phase with ethanol/water as the eluting solvent.
The cytidine derivative (4d) was synthesized from uridine 3c which was treated first with a solution of phosphorus oxychloride and 1,2,4-triazole in pyridine, followed by treatment with NH 4 In summary, the hitherto unknown bicyclo [2.2.1] carbocyclic nucleosides have been prepared. These compounds maintain the 1,3-cis-relationship between the nucloside base and the hydroxyl group. In vitro anti-HIV studies showed that the target compounds were inactive. Further antiviral studies are in progress and will be reported elsewhere.
Experimental Section
General Procedures. Melting points reported were uncorrected and were determined on an Electrothermal Engineering Ltd. melting point apparatus. Ultraviolet (UV) spectra were recorded on a Cary 3 UV-Visible spectrophotometer.
1 H NMR and 13 C NMR were recorded on a AC-300 and WM-360 instruments. Chemical shifts are referenced to an internal TMS standard for 1H-NMR spectra and to solvent (CDCl 3 , DMSO-d 6 , Acetone-d 6 or CD 3 OD) for 13 C NMR spectra. Column chromatographic separations were carried out using 230-400 mesh silica gel. HPLC separations were carried out at 80 psi on Altex columns packed with Amberlite XAD-4 resin. Fractions were monitored by a Pharmacia UV-2 ultraviolet monitor and were collected on a Gilson FC-100 fraction collector. Purities of intermediates and final products were determined by a combination of 1 H and 13 C NMR spectra, quantitative UV data and HPLC analysis. ol (5a) . To a solution of 3a (0.55g, 2.4 mmole) in THF (25 mL) was added 1.0M BH 3 ·THF (9.7 mL, 9.7 mmole) at 0 °C. The resulting solution was warmed to room temperature and stirred for 5 h. It was quenched with water, followed by treatment with 30% H 2 O 2 and 2N NaOH (aq). It was neutralized with dil. HCl. The solvent was removed under reduced pressure and then the residue was purified on silica gel with 15-20% methanol/chloroform to give a mixture of two isomers, 4a and 5a (0.5 g, 2.039 mmol, 80%). The two regioisomers were separated by reversed-phase HPLC with water-ethanol as the eluting solvent. Spectral data for 4a (45%): mp 199-201 °C, 1 
2-(S)-[6-Amino-9(H)-purin-9-yl]]-5-norbornene (3a

2(S)-[3, 4-Dihydro-2, 4-dioxo-5-methyl-1(2H)-pyrimidinyl]-norbornan-6 (R) -ol (4b) and 2(S)-[3,4-dihydro-2,4-dioxo-5-methyl-1(2H)-pyrimidinyl]-norbornan-5(S)-ol (5b).
To a solution of 3b (0.25g, 1.15 mmole) in THF (20 mL) was added 1.0M BH 3 ·THF (2.86 ml, 2.86 mmol) at 0°C.. The resulting solution was warmed to room temperature and stirred for 5 h and worked up as described for 4a and 5a to give the regioisomers, 4b and 5b (70 mg, 0.296 mmol, 26%). The two isomers were separated by reversed-phase HPLC with water-ethanol as the eluting solvent. Data for 4b: mp 98-100 °C (lyophilized powder); 1H NMR ( 
2(S)-[3,4-Dihydro2,-4-dioxo-1 (2H)-pyrimidinyl]-norbornan-6 (R)-ol (4c) and 2(S)-[3,4-dihydro-2, 4-dioxo-1(2H)-pyrimidinyl]-norbornan-5(S)-ol (5c).
Intermediate 3c was prepared as described for 3b (yield: 56%): 
2(S)-[4-Amino-2-oxo-1(2H)-pyrimidinyl]-5-norbornene (3d).
To a solution of 3c (0.18 g, 0.88 mmole) in pyridine (7 mL) was added phosphorus oxychloride (0.16 ml, 1.76 mmol) and 1,2,4-triazole (0.24 g, 3.52 mol) in pyridine (7 mL) at 0 °C. The resulting solution was warmed to room temperature and stirred for 26 h, followed by treatment with NH 4 OH (2 ml, 17.6 mmole) and further stirring for 12 h. The solvent was removed and the residue was purified on silica gel with 10-15% methanol/chloroform to give 3d (60 mg, 0.295 mmol, 34% yield). 
2(S)-[4-Amino-2-oxo-1(2H)-pyrimidinyl]-norbornan-6(R)-ol (4d) and 2(S)-[4-Amino-2-oxo-1(2H)-pyrimidinyl]-norbornan-5(S)-ol (5d).
Compounds 4d (31%) and 5d (6%) were prepared by hydroboration followed by oxidation as described for 4a and 5a. Data for 4d: 1H NMR (CD 3 
